TEVA - חוב כולל להון Teva Pharmaceuticals

Teva Pharmaceutical Industries (TEVA) combines leadership in affordable generics with the development of high-cost neurology drugs. The dynamics of the company's financial dependence on the GURU.Markets terminal chart reflect a turning point driven by the global distribution ecosystem and growth in biosimilar sales. Meanwhile, the 2.12 level is a current metric confirming cost optimization and a reduction in the business's debt load.

Investors must assess the risk of insolvency when holding shares over the long term. This ratio is calculated as the sum of all liabilities divided by equity, determining the level of leverage. By analyzing the current debt-to-equity load, one can judge the business's degree of dependence on external loans. For Teva Pharmaceutical Industries (TEVA), this balance is critical when financing costly biosimilars. Optimal leverage allows the company to combine the mass production of affordable medicines with capital-intensive innovative developments.